Download PDF
Hamostaseologie 2005; 25(02): 209-212
DOI: 10.1055/s-0037-1619653
Original Article
Schattauer GmbH

Gerinnungsaktive Therapeutika

Antithrombin, FFP, PPSB, FXIII, rFVIIaReplacement therapy of coagulation factor preparationsantithrombin, FFP, PPSB, FXIII, rFVIIa
I. Scharrer
1   Hämostaseologie (Leiterin: Prof. Dr. med. Inge Scharrer), J.W. Goethe Universitätskliniken Frankfurt am Main
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Gerinnungsaktive Therapeutika (AT, FFP, PPSB, FXIII, rFVIIa) werden auf der Intensivstation häufig eingesetzt.

Indikationen, Dosierung, spezifische Effekte und Nebenwirkungen sind dabei zu beachten.

Summary

Replacement therapy of coagulation factor preparations (AT, FFP, PPSB, FXIII, rFVIIa) are frequently used on the Intensive Care Units.

Indications, dosage, specific effects and side effects have to be considered.

Schlüsselwörter

Antithrombin - Fresh-frozen-Plasma - FVIIa - FXIII

Keywords

Antithrombin - fresh frozen plasma - FVIIa - FXIII
 

  • Literatur

  • 1 Al Douri M, Shafi T, Al Khudairi D. et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 01) 121-7.
    CrossrefPubMedGoogle Scholar
  • 2 Ameri A, Stolte S. Correlation of activated clotting time (ACT) with rFVIIa infusion and clinical efficacy in a patient with Glanzmann Thrombasthenia and platelet alloantibodies. Thromb Haemost 2002; 87: 1084.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Beeck H, Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998; 74 (Suppl. 01) 219-23.
    CrossrefPubMedGoogle Scholar
  • 4 Berntorp E. Recombinant FVIIa in the treatment of warfarin bleeding. Sem Thromb Hemost 2000; 26: 433-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Comp PC. Control of coagulation reactions. In: Wiliams WJ, Beutler E, Erslev AJ. et al. (eds). Hematology. 4th International Edition. New York: McGraw-Hill; 1991: 1304-12.
    Google Scholar
  • 6 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-30.
    PubMedGoogle Scholar
  • 7 Erhardtsen E. Ongoing NovoSeven® trials. Intensive Care Med 2002; 28: 248-55.
    CrossrefPubMedGoogle Scholar
  • 8 Fourrier F, Chopin C, Huart JJ. et al. Double-blind placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-8.
    CrossrefPubMedGoogle Scholar
  • 9 Friederich PW, Geerdink H, Keller TT. et al. Novel application of recombinant factor VIIa: the effect of the administration of recombinant activated VII (NovoSeven) on perioperative blood loos in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Infus Ther Transfus Med 2001; 28: 112-3.
    PubMedGoogle Scholar
  • 10 Gerotziafas GT, Zervas C, Gavrielidis G. et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and lifethreatening haemorrhage. Am J Hematol 2002; 69: 219-22.
    CrossrefPubMedGoogle Scholar
  • 11 Grossmann RE, Geisen U, Schwender S. et al. Continuous infusion of recombinant factor VIIa (NovoSeven®) in the treatment of a patient with Type III von-Willebrand’s disease and alloantibodies against von-Willebrand factor. Thromb Haemost 2000; 83: 633-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemostas 1997; 78: 1463-7.
    PubMedGoogle Scholar
  • 13 Hedner U, Erhardtsen E. Potential role for rhFVIIa in transfusion medicine. Transfusion 2002; 42: 114-24.
    CrossrefPubMedGoogle Scholar
  • 14 Hellstern P, Beeck H, Fellhauer A. et al. for the PCC Study Group. Factor VII and Activated-Factor-VII Content of Prothrombin Complex Concentrates. Vox Sang 1997; 73: 155-61.
    CrossrefPubMedGoogle Scholar
  • 15 Heuer L, Blumenberg D. Rekombinanter Faktor VIIa (NovoSeven®). Ein Überblick über aktuelle und mögliche zukünftige Indikationen. Anaesthesist 2002; 51: 388-99.
    CrossrefPubMedGoogle Scholar
  • 16 Jurlander B, Thim L, Klausen N. et al. Recombinant activated factor VII (rhFVIIa): Characterisation, manufacturing and clinical development. Sem Thromb Haemostas 2001; 27: 373-83.
    PubMedGoogle Scholar
  • 17 Kenet G, Walden R, Eldad A. et al. Surgical intervention failed to stop life-threatening bleeding caused by injury complicated by severe coagulopathy. Administration of recombinant factor VIIa immediately corrected the coagulopathy and stopped bleeding. Lancet 1999; 345: 1879.
    PubMedGoogle Scholar
  • 18 Klein H, Dodd RY, Czik WH. et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998; 38: 102-7.
    CrossrefPubMedGoogle Scholar
  • 19 Köhler M. et al. Virusinaktiviertes Plasma. Infusionsther Transfusionsmed 1994; 21 (Suppl. 01) 73-6.
    PubMedGoogle Scholar
  • 20 Lane DA, Bayston T, Olds RJ. et al. Antithrombin mutation database: 2nd (1977) update. Thromb Haemost 1997; 77: 197-211.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Lucia JF, Aguilar C, Orna E. et al. Successful outcome of a cirrhotic patient with postoperative haematuria treated with a single high dose of recombinant factor VIIa. Haemophilia 2001; 7: 600-2.
    CrossrefPubMedGoogle Scholar
  • 22 Monroe DM, Hoffmann M, Oliver JA. et al. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinol 1998; 9 (Suppl. 01) 15-20.
    PubMedGoogle Scholar
  • 23 Muszek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: Structure and function. Thromb Res 19999 94: 271-305.
    PubMedGoogle Scholar
  • 24 Nijenhuis AVM, van Bergeijk L, Huijgens PC. et al. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematology 2004; 89: ECR 14.
    PubMedGoogle Scholar
  • 25 O’Shaughnessy DF, Atterbury C, Bolton Maggs P. et al. Guidelines for the use of fresh-frozen-plasma, cryoprecipitate and cryosupernatant. The British Society for Haematology 2004; 126: 11-28.
    PubMedGoogle Scholar
  • 26 Oldenburg J, Hertfelder HJ, Brackmann HH. et al. Eigenschaften und Indikationen von PPSB-Konzentraten unter besonderer Berücksichtigung der Qualitätssicherung sowie flankierender therapeutischer Maßnahmen. Infusionsther Transfusionsmed 1996; 23: 271-80.
    PubMedGoogle Scholar
  • 27 Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Current Opin Hematol 2001; 8: 312-8.
    PubMedGoogle Scholar
  • 28 Preston FE, Laidlaw ST, Sampson B. et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116: 619-24.
    CrossrefPubMedGoogle Scholar
  • 29 Römisch J, Bonik K, Diehl KH. et al. Vergleichende In-vitro-Untersuchung von drei Prothrombinkomplex-Konzentraten (PPSB). Med Welt 1997; 48: 205-11.
    PubMedGoogle Scholar
  • 30 Rosenberg RD. Actions and interaction of antithrombin and heparin. N Engl J Med 1975; 292: 146-51.
    CrossrefPubMedGoogle Scholar
  • 31 Scharrer I. on behalf of the German NovoSeven Study Group. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
    CrossrefPubMedGoogle Scholar
  • 32 Schregel W, Straub H, Wölk G. et al. Erfolgreiche Therapie einer Verbrauchskoagulopathie bei EPH-Gestose mit mehrfachem Organversagen. Anaesth Intensivther Notfallmed 1984; 19: 201-3.
    PubMedGoogle Scholar
  • 33 Sutor AH, Bruhn HD, Schreiber R. et al. Thrombosen im Kindesalter. Hämostaseologie 1992; 12: 82-93.
    Article in Thieme ConnectPubMedGoogle Scholar